
Peter H SÅ'nksen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4276094/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison of normal distribution–based and nonparametric decision limits on the GHâ€2000 score for detecting growth hormone misuse (doping) in sport. Biometrical Journal, 2021, 63, 187-200.	1.0	4
2	The effects of recombinant human insulinâ€like growth factorâ€1/insulinâ€like growth factor binding proteinâ€3 administration on lipid and carbohydrate metabolism in recreational athletes. Clinical Endocrinology, 2021, 94, 551-562.	2.4	2
3	Exact statistical calculation of the uncertainty term in the decision limits of the GH-2000 score for growth hormone misuse (doping) detection. Statistical Methods in Medical Research, 2019, 28, 928-936.	1.5	4
4	Hyperandrogenism controversy in elite women's sport: an examination and critique of recent evidence. British Journal of Sports Medicine, 2018, 52, 1481-1482.	6.7	31
5	Determination and regulation of body composition in elite athletes. British Journal of Sports Medicine, 2018, 52, 219-229.	6.7	15
6	A correction to the age-adjustment of the GH-2000 score used in the detection of growth hormone misuse. BMC Research Notes, 2018, 11, 650.	1.4	4
7	Use and misuse of hormones in sport. Lancet Diabetes and Endocrinology,the, 2016, 4, 882-883.	11.4	6
8	Authors' response to letter by Ritzen <i>etÂal</i> . (Published online 25 July 2014, DOI: 10.1111/cen.12531). Clinical Endocrinology, 2015, 82, 308-309.	2.4	2
9	Medical and Ethical Concerns Regarding Women With Hyperandrogenism and Elite Sport. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 825-827.	3.6	26
10	The development of decision limits for the CHâ€2000 detection methodology using additional insulinâ€like growth factorâ€l and aminoâ€terminal proâ€peptide of type III collagen assays. Drug Testing and Analysis, 2015, 7, 745-755.	2.6	26
11	The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3126-3131.	3.6	11
12	The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: Physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH- 2000 detection score: Authors' response. Clinical Endocrinology, 2010, 73, 274.	2.4	3
13	The International Olympic Committee (IOC) and GH-2000. Growth Hormone and IGF Research, 2009, 19, 341-345.	1.1	16
14	Pituitary incidentaloma. Clinical Endocrinology, 2008, 69, 180-180.	2.4	6
15	Commentary on Graham et al.: Physical Effects of Short-Term rhGH Administration in Abstinent Steroid Dependency. Hormone Research in Paediatrics, 2008, 69, 355-356.	1.8	1
16	Lies, damn lies and statistics. Growth Hormone and IGF Research, 2005, 15, 173-176.	1.1	5
17	Specialised information systems: diabetes care. Studies in Health Technology and Informatics, 2002, 65, 231-49.	0.3	0
18	Computer assisted learning is an effective way of teaching endocrinology. Clinical Endocrinology, 2001, 55, 537-542.	2.4	29

Peter H SÅ'nksen

#	Article	IF	CITATIONS
19	Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clinical Endocrinology, 1998, 49, 739-746.	2.4	40
20	Acromegaly and colonic cancer. Clinical Endocrinology, 1997, 47, 647-648.	2.4	11
21	Using a mixture model to predict the occurrence of diabetic retinopathy. Statistics in Medicine, 1995, 14, 2599-2608.	1.6	0
22	Growth Hormone Replacement Therapy for Growth Hormone-Deficient Adults. Drugs, 1995, 49, 656-663.	10.9	30
23	Glyoxalase System in Clinical Diabetes Mellitus and Correlation with Diabetic Complications. Clinical Science, 1994, 87, 21-29.	4.3	512
24	Evidence against the formation of 2-amino-6-(2-formyl-5-hydroxymethyl-pyrrol-l-yl)-hexanoic acid ('pyrraline') as an early-stage product or advanced glycation end product in non-enzymic protein glycation. Clinical Science, 1993, 84, 87-93.	4.3	27
25	Modification of the glyoxalase system in clinical diabetes mellitus. Biochemical Society Transactions, 1993, 21, 158S-158S.	3.4	12
26	Population genetics of human glyoxalases and the development of diabetic complications. Biochemical Society Transactions, 1993, 21, 172S-172S.	3.4	2
27	Basal metabolic rate in adults with growth hormone deficiency and in patients with acromegaly: relationship with lean body mass, plasma insulin level and leucocyte sodium pump activity. Clinical Science, 1992, 83, 325-330.	4.3	36
28	Regulation of Glucose Production in vivo. Biochemical Society Transactions, 1978, 6, 1134-1138.	3.4	0